XML 97 R75.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments - BeiGene (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Jan. 02, 2020
Net Investment Income [Line Items]            
Payments to Acquire Equity Method Investments     $ 157 $ 3,219 $ 24  
BeiGene            
Net Investment Income [Line Items]            
Ownership percentage   18.40% 18.40% 20.50%   20.50%
Equity Method Investment, Aggregate Cost           $ 2,800
Equity Method Investment, Quoted Market Value   $ 5,100 $ 5,100 $ 4,900   2,600
Equity Method Investment, Difference Between Carrying Amount and Underlying Equity           2,400
Payments to Acquire Equity Method Investments     50 569    
Equity Method Investment, Change In Carrying Value, Other     265 34    
Company's share of profits (losses) of related party     265 229    
Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity     172 109    
Approximate carrying value of the company's equity method investment   2,800 2,800 2,900    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Equity Method Investment, Quoted Market Value   $ 5,100 $ 5,100 $ 4,900   $ 2,600
BeiGene | Minimum [Member]            
Net Investment Income [Line Items]            
Finite-Lived Intangible Asset, Useful Life     8 years      
BeiGene | Maximum [Member]            
Net Investment Income [Line Items]            
Finite-Lived Intangible Asset, Useful Life     15 years      
Neumora Therapeutics, Inc.            
Net Investment Income [Line Items]            
Ownership percentage 25.90% 25.90% 25.90%      
Equity Method Investment, Aggregate Cost $ 257          
Equity method investment, change in carrying value   $ 37        
Payments to Acquire Equity Method Investments $ 100